Pharma BD Deal Intelligence

Sanofi SA / Genzyme Corporation

2010 · Acquisition/Merger · $18.5B · Complete

Sanofi-aventis submitted a non-binding proposal to acquire Genzyme for approximately $18.5B ($69/share) on August 29, 2010. Final definitive agreement reached February 16, 2011 at $74/share plus CVR (~$20.1B total). Closed April 8, 2011.

Did it work? Outcome assessment

Assessment window: 15yr post-close.

Key facts

• Announced Aug 29, 2010
• Closed Apr 08, 2011
• Deal value $18.5B
• Deal type Acquisition/Merger
• Therapeutic area Lysosomal storage disorders; multiple sclerosis
• Indications Lysosomal storage disorders; multiple sclerosis
• Key assets Cerezyme; Fabrazyme; Lemtrada (alemtuzumab)
• Mechanism Enzyme replacement therapy; anti-CD52 monoclonal antibody

← Browse all deals  ·  How we score deals